In the study which compared blood samples from 30 patients with PD to 30 healthy individuals, AGO2 (Argonaute 2) was reduced by a statistically significant level. AGO2 is important in the regulation of alpha-synuclein accumulation in the brain and dysregulation can lead to motor control impairment. The change was not observed in late-stage PD patients – with the company saying that the trend could be related to disease onset.
NeuroSense reports encouraging preliminar... - Cure Parkinson's
NeuroSense reports encouraging preliminary results from PD study
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Prism PD Study
I think this is the NLY01 clinical trial. NLY01 is a pegylated form of exenatide, may be...
Fecal microbiota transplantation (FMT) therapy for Parkinson’s disease - A preliminary study in China
"The objective of this study was to assess the efficacy and safety of FMT on PD. Fifteen PD...
Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD
Highlights
• Oral NR increases brain NAD levels in individuals with Parkinson’s disease
• NR...
PD subgroups and subtypes : preliminary comments, initial bibliography
The discussion of subgroups is important. "Subtypes" seems an
equivalent word (1). Much...
Nilo - PD Study
MJFF announced an exciting second study to test Nilotinib ( The approved drug used for Cronic...
Related Posts
Encouraging Stem Cell Trial Results 
Another New And Completed FMT Study In 54 PwP Showing Clearly Positive Results Using Freeze Dried Oral FMT
New Clinical Trial Starting: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (REGENERATE-PD)
Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease 2021
READ this ENCOURAGING study on Vielight and Photobiomodulation (PMB)!
